Publications
1. Lovera J, Hayes A, Brennan K, Adams-Hogan F. Immune-mediated inflammatory demyelinating dysfunction
of the nervous system. South Med J. 2002;95(10):1229-1231.
2. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent T cell
receptor peptide vaccine for multiple sclerosis. Mult Scler. 2005;11(5):552-561.
3. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005;11(2):159-165.
4. Lovera J, Bagert B, Smoot KH, et al. Correlations of Perceived Deficits Questionnaire of Multiple
Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological
tests. J Rehabil Res Dev. 2006;43(1):73-82.
5. Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis:
Potential effects of medications with central nervous system activity. J Rehabil Res
Dev. 2006;43(1):83-90.
6. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance
in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13(3):376-385.
7. Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with
a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression
and TCR recognition in subjects with multiple sclerosis. Immunology. 2008;123(1):66-78.
8. Hugos CL, Copperman LF, Fuller BE, Yadav V, Lovera J, Bourdette DN. Clinical trial of a formal group fatigue program in multiple sclerosis.
Mult Scler. 2010;16(6):724-732.
9. Kim E, Lovera J, Schaben L, Melara J, Bourdette D, Whitham R. Novel method for measurement of fatigue
in multiple sclerosis: Real-Time Digital Fatigue Score. J Rehabil Res Dev. 2010;47(5):477-484.
10. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis:
a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715-723.
11. Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, Whitham R. American ginseng does not improve fatigue in
multiple sclerosis: a single center randomized double-blind placebo-controlled crossover
pilot study. Mult Scler. 2011;17(12):1523-1526.
12. Lovera J, Kovner B. Cognitive impairment in multiple sclerosis. Curr Neurol Neurosci Rep.
2012;12(5):618-627.
13. Lovera J, Kim E, Heriza E, et al. Ginkgo biloba does not improve cognitive function in MS:
a randomized placebo-controlled trial. Neurology. 2012;79(12):1278-1284.
14. Mohr DC, Lovera J, Brown T, et al. A randomized trial of stress management for the prevention of new
brain lesions in MS. Neurology. 2012;79(5):412-419.
15. Lovera J, Reza T. Stress in multiple sclerosis: review of new developments and future directions.
Curr Neurol Neurosci Rep. 2013;13(11):398.
16. Cameron MH, Peterson V, Boudreau EA, et al. Fatigue is associated with poor sleep
in people with multiple sclerosis and cognitive impairment. Mult Scler Int. 2014;2014:872732.
17. Lovera J, Villemarette-Pittman N. Tumefactive multiple sclerosis and fingolimod. J Neurol
Sci. 2014;344(1-2):1-2.
18. Devier DJ, Lovera JF, Lukiw WJ. Increase in NF-kappaB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis
(MS) and pro-inflammatory neurodegeneration. Front Mol Neurosci. 2015;8:5.
19. Hughes AJ, Hartoonian N, Parmenter B, et al. Cognitive Impairment and Community
Integration Outcomes in Individuals Living With Multiple Sclerosis. Arch Phys Med
Rehabil. 2015;96(11):1973-1979.
20. Lovera J, Ramos A, Devier D, et al. Polyphenon E, non-futile at neuroprotection in multiple
sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized
placebo-controlled studies. J Neurol Sci. 2015;358(1-2):46-52.
21. Chachkhiani, D., Isakadze, M., Villemarette-Pittman, N.R., Devier, D.J., & Lovera, J.F. (2021). Altered Mental Status Predicts Length of Stay But Not Death in a Community-based
Cohort of Hospitalized COVID-19 Patients. Clinical Neurology and Neurosurgery, 210,
https://doi.org/10.1016/j.clineuro.2021.106977
